MP79-18 RESULTS OF THE CLINICAL TRAIL IN-VIVO ISOLATION OF CTCS IN PROSTATE CANCER PATIENTS BY A CELLCOLLECTOR (2014)

You have accessJournal of UrologyProstate Cancer: Markers II1 Apr 2014MP79-18 RESULTS OF THE CLINICAL TRAIL IN-VIVO ISOLATION OF CTCS IN PROSTATE CANCER PATIENTS BY A CELLCOLLECTOR Gerit Theil, Kersten Fischer, Andre Schumann, Kathrin Haublod, Catrin Boehm, Thomas Krahn, Klaus Luecke, Nils Morgenthaler, and Paolo Fornara Gerit TheilGerit Theil More articles by this author , Kersten FischerKersten Fischer More articles by this author , Andre SchumannAndre Schumann More articles by this author , Kathrin HaublodKathrin Haublod More articles by this author , Catrin BoehmCatrin Boehm More articles by this author , Thomas KrahnThomas Krahn More articles by this author , Klaus LueckeKlaus Luecke More articles by this author , Nils MorgenthalerNils Morgenthaler More articles by this author , and Paolo FornaraPaolo Fornara More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2014.02.2521AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Circulating tumor cells (CTCs) in the blood stream play a critical role in establishing metastases. The clinical value of CTCs as a biomarker may help to assess the treatment efficacy. The detection of CTCs in the blood of patients with prostate cancer might therefore, in addition to their prognostic value, serve as liquid biopsy, complementing or replacing prostate-specific antigen (PSA) determination in predicting and monitoring the response to different therapies. However, capturing these rare cells from whole blood is still a major challenge that needs significant improvement. The aim was to demonstrate proof of concept of in vivo CTC isolation in Prostate cancer patients (PCa). METHODS A medical device (CellCollector) was inserted in a cubital vein for 30 minutes. The interaction of target CTCs with the CellCollector was mediated by antibodies to the epithelial cell adhesion molecule (EpCAM). To confirm binding of CTCs to the wire, immunohistochemical staining against Cytokeratin and CD45 was performed. There were 226 applications of the device in 16 metastasized PCa (PCa-m) with up to 8 wire applications per patient, 24 localized PCa (PCa-l) with up to 3 wire applications per patient as well as 19 men with benign prostate hypertrophy (BPH) and 21 women as control group with only one wire application. CTC counts from 22 PCa patients with 71 applications were directly compared to the CellSearch technology. RESULTS We obtained in vivo isolation of CTCs in 73 of 98 applications to PCa patients (74.5 %). The sensitivity for metastasized PCa was (86.2%) and for local PCa (57.5%), respectively. In PCa-l patients we observed prior radical prostatectomy (n=18) and 6 (n=15) and 12 (n=7) months after surgery CTC numbers on average of 18.2, 2.8 and 1.4, respectively. For the CellSearch® measurements, a blood draw of 7.5 ml blood was performed. We found in 77.5% (55/71) applications the patient to be positive for CTCs using the CellCollector™. In contrast the CellSearch® system resulted only in 42.2% (30/71) in the detection of CTCs. In addition we found a correlation of the CTC levels detected by the CellCollector™ and the PSA level during treatment. CONCLUSIONS We demonstrate the use of CTCs besides PSA during therapy adjustment in PCa patients. In summary, the CTC detection rate of the CellCollector in PCa-m and PCa-l in comparison to the CellSearch® method increased by 26% and 45%. Further molecular genetic CTC characterization as well as multiple antibody coating at the CellCollector will assume crucial information for therapy decisions. © 2014FiguresReferencesRelatedDetails Volume 191Issue 4SApril 2014Page: e936-e937 Advertisement Copyright & Permissions© 2014Metrics Author Information Gerit Theil More articles by this author Kersten Fischer More articles by this author Andre Schumann More articles by this author Kathrin Haublod More articles by this author Catrin Boehm More articles by this author Thomas Krahn More articles by this author Klaus Luecke More articles by this author Nils Morgenthaler More articles by this author Paolo Fornara More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...